“Bristol-Myers to buy heart drugs developer MyoKardia for about $13 billion”
October 5, 2020
“Bristol-Myers Squibb said on Monday it would buy MyoKardia for about $13 billion to bolster its portfolio of heart disease treatments, as it seeks to reduce some of its dependence on cancer drugs.
The deal follows Bristol-Myers’ $74 billion acquisition of Celgene last year that combined two of the world’s largest cancer drug businesses in the biggest pharmaceutical deal ever.
Shares of MyoKardia, which have nearly doubled in value this year, surged another 58.5% to $221.25 before the opening bell, just shy of Bristol Myers’ offer price of $225 per share…”